Monopar Therapeutics MNPR
NASDAQ MNPR
$74.59 +0.36 (+0.48%)
As of: Oct 21, 2026 · 10:23 AM EDT

Monopar Therapeutics (MNPR) Debt Ratio (2020)

Updated

Monopar Therapeutics' Debt Ratio came in at 0.01 for Q3 2020, down 29.5% from the prior quarter.

Analysis

Monopar Therapeutics (MNPR) Debt Ratio (2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Eli Lilly 1,132.34 Bn 1,100.93 Bn 19.71 Bn 0.39
2 Johnson & Johnson 615.91 Bn 534.44 Bn 17.26 Bn 0.24
3 AbbVie 505.47 Bn 478.59 Bn 12.70 Bn 0.52
4 Merck 368.25 Bn 322.63 Bn 12.21 Bn 0.42
5 Novartis Ag 298.18 Bn 262.17 Bn 11.24 Bn 0.08
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn 0.28
7 Amgen 236.22 Bn 191.62 Bn 7.24 Bn 0.60
8 Gilead Sciences 190.68 Bn 164.87 Bn 6.22 Bn 0.53
9 Pfizer 170.14 Bn 116.79 Bn 10.94 Bn 0.31
10 Monopar Therapeutics 637.18 Mn 355.41 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 0.01
Jun 30, 2020 0.01
API Access

Monopar Therapeutics Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=MNPR&period=max&api_key=YOUR_API_KEY